Secondary hyperaldosteronism associated with severe infantile atopic dermatitis: a case series

Article information

Ann Pediatr Endocrinol Metab. 2026;31(4):247-252
Publication date (electronic) : 2025 December 27
doi : https://doi.org/10.6065/apem.2550320.160
1Department of Paediatric Nephrology, Evelina Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
2Department of Clinical Biochemistry (Synnovis), Kings College Hospital NHS Foundation Trust, London, UK
3Department of Paediatrics, University Hospital Lewisham, Lewisham and Greenwich NHS Foundation Trust, London, UK
4Faculty of Life Sciences and Medicine, King's College London, London, UK
5Department of Paediatric Endocrinology, Variety Children's Hospital, King's College Hospital NHS Foundation Trust, London, UK
Address for correspondence: Aimée M.M.C. Jacquemot Department of Paediatric Nephrology, Evelina Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, 158 Andrewes House, Barbican, London, EC2Y8BA Email: aimee.jacquemot@nhs.net
Received 2025 August 29; Revised 2025 October 28; Accepted 2025 November 1.

Abstract

Recent literature has highlighted an association between severe atopic dermatitis (AD) in infancy and biochemical disturbances consistent with secondary hyperaldosteronism. Transepidermal sodium loss driving volume depletion has been hypothesized to contribute to this process, but direct evidence of the underlying mechanisms remains sparse. We present a case series of 3 children, aged 3 to 7 months, who were admitted with severe exudative eczema associated with hyponatremia and hyperkalemia, despite evidence of effective renin-angiotensin-aldosterone system activation and renal mineralocorticoid action. In each case, these biochemical and hormonal disturbances resolved after optimizing dermatological and nutritional management of their atopic presentations, supporting the role of extrarenal mechanisms of electrolyte disturbance. Our case series highlights the importance of considering biochemical and hormonal factors in the comprehensive early treatment of infantile AD to prevent complications associated with electrolyte imbalances and nutritional deficiencies.

Highlights

· Severe infantile atopic dermatitis can be complicated by hyponatremia and hyperkalemia despite effective renin-angiotensin-aldosterone system activation and renal mineralocorticoid action, consistent with secondary hyperaldosteronism.

· These electrolyte and hormonal disturbances likely arise from extrarenal sodium and fluid losses through the skin and gastrointestinal tract, compounded by malnutrition and reduced circulating volume.

· Prompt optimization of dermatological and nutritional management resolved these disturbances, supporting early, holistic treatment of infantile atopic dermatitis to prevent electrolyte and nutritional complications.

Introduction

Aldosterone plays a central role in sodium and potassium homeostasis as part of the renin-angiotensin-aldosterone system (RAAS). It regulates effective circulating volume (ECV) and blood pressure by promoting sodium reabsorption through mineralocorticoid receptors in the kidneys [1,2]. Disorders of aldosterone synthesis, therefore, typically present with hyponatremia, hyperkalemia and hypovolemia. These biochemical changes are also seen in pseudohypoaldosteronism (PHA), associated with elevated renin and aldosterone levels due to end-organ resistance [3]. Inherited forms of PHA typically present in early infancy with dehydration and salt-wasting, despite normal glomerular filtration (GFR), renal and adrenal function, while acquired, transient, mineralocorticoid resistance (secondary PHA) can also occur in children taking certain medications or with obstructive or infectious renal disease [3].

However, biochemical profiles similar to those seen in PHA have also been shown to occur in the absence of mineralocorticoid resistance, secondary to severe extrarenal sodium loss [4]. In such cases, elevated aldosterone levels reflect an appropriate response to intravascular volume depletion and hyponatremia, representing a pattern of secondary (physiological) hyperaldosteronism. This is characteristically seen in conditions that reduce ECV, such as heart failure and nephrotic syndrome, or impaired renal perfusion from renal artery stenosis or Nutcracker syndrome [1,5]. This case series highlights 3 infants with severe exudative eczema who developed profound hyponatremia and hyperkalemia despite evidence of marked RAAS activation and preserved renal responsiveness to aldosterone.

While secondary PHA has classically been described in early infancy, commonly under 3 months of age, and associated with urinary tract infection or congenital renal malformation, the cases described here occurred in older infants without identifiable renal pathology. This likely reflects a distinct, less well-characterized mechanism of electrolyte dysregulation in the context of severe exudative atopic dermatitis (AD). In these cases, prolonged transepidermal and gastrointestinal sodium and water losses appear to drive intravascular volume depletion, leading to RAAS activation with preserved aldosterone responsiveness. Consequently, the biochemical profile mimics secondary PHA but is more accurately explained by secondary (physiological) hyperaldosteronism rather than true aldosterone resistance.

Case reports

1. Case 1

Patient 1 presented at 3 months of age with severe, exudative eczema unresponsive to emollients, 1% hydrocortisone and fusidic acid. She was exclusively breastfed, with longstanding reflux and vomiting after feeds, for which her mother had excluded cow’s milk from her diet. The patient was referred to allergy, dietetics, and dermatology services, and her treatment was escalated to include Fucidin H and topical tacrolimus. On review at 9 months of age, there was some improvement in eczema control, but she remained predominantly breastfed with severe aversive feeding, despite thickeners and exclusion of allergens from her mother’s diet after skin prick testing. Her weight dropped below the 0.4th centile, and blood tests showed marked deficiencies of iron, vitamin D and sodium with severe hyperkalemia. Due to the acute electrolyte imbalance and failure to thrive, she was admitted for supplementation and nasogastric feeding. During her admission, the initial hyponatremia (129 mmol/L) and hyperkalemia (7.4 mmol/L) improved (Table 1), normalizing a few days after discharge. Her renal function and renal ultrasound were normal throughout with low urinary sodium concentration (8 mmol/L). A urinary steroid profile requested while she was hyponatremic showed features of PHA, with increases of aldosterone precursors, corticosterone and aldosterone metabolites, excluding all saltwasting forms of congenital adrenal hyperplasia (CAH) and aldosterone synthase deficiency. Further endocrine investigations were performed 2 months after discharge showing normal sodium and potassium levels with borderline high aldosterone level of 6,750 pmol/L (indicative age-related range <1,000 pmol/L), normal renin activity and improvement in eczema control (Table 1). At 20 months of age, her aldosterone had normalized, with no aversive eating symptoms, eczema flares occurring less than monthly and her weight tracking the 50th centile (Table 2).

Laboratory results

Weight trends – from birth, pre-, and posttreatment

2. Case 2

Patient 2 presented at 7 months with 24 hours of lethargy and vomiting after feeds. His eczema had been managed with emollients, 1% hydrocortisone and fusidic acid, and now appeared to be infected and exudative. Formula had recently been added to his diet, after 6 months of exclusive breastfeeding, with his mother following a vegan diet. His weight was below the 0.4th centile (21st at birth). Initial blood tests showed marked hyponatremia of 115 mmol/L and hyperkalemia of 6.4 mmol/L with normal renal function (Table 1). This was associated with aldosterone levels >40,000 pmol/L (indicative age-related range < 2,000 pmol/L) and an elevated plasma renin activity of 22.4 nmol/L/h (indicative agerelated range <11 nmol/L/hr). An elevated white blood cell count of 40.6×109/L (lymphocytes 17.9×109/L, eosinophils 13×109/L, no blasts) and thrombocytosis were also noted. Patient 2 was admitted for intravenous fluids given his hyponatremia and IV flucloxacillin for infected eczema. Dermatology optimized his steroid regimen, and an amino acid formula was started due to concerns regarding cow’s milk protein allergy (CMPA). He was discussed with endocrinology and discharged with a sodium of 131 mmol/L (sodium level at the point of discharge from admission). On review at 11 months, his eczema and weight had improved (Table 2) – skin prick testing showed sensitization to milk, nuts, lentils and coconut, and so continued exclusion of these foods was recommended. Repeat bloods showed complete resolution of the electrolyte disturbances and normalization of aldosterone and renin levels.

3. Case 3

Patient 3 was reviewed at 5 months of age with a week of cough, vomiting, lethargy and severe exudative eczema. This had worsened over the last 2 months despite emollients, 1% hydrocortisone and maternal dairy and soya exclusion. He was admitted for IV antibiotics and started on potent topical steroids by dermatology. His laboratory results initially showed a metabolic acidosis with hyponatremia (sodium 121 mmol/L), hyperkalemia (potassium 6.3 mmol/L), with normal renal function including ultrasound and marked leukocytosis without blasts – white cell count 49.2 (lymphocytes 18.2×109/L, eosinophils 19.7×109/L). A urine sample taken in the Emergency Department (ED) showed low sodium excretion and urinary steroid profiling "consistent with PHA and excluding all salt-wasting forms of CAH and aldosterone synthase deficiency" (increased corticosterone and aldosterone metabolites – Table 1). He was initially treated in ED with a fluid bolus and initiation of maintenance fluids and sodium supplementation of 3 mmol/kg/day. Once on the ward, further investigations were performed showing mildly raised aldosterone levels at 3,360 pmol/L (indicative age-related range <2,000 pmol/L) and elevated renin levels of 88.3 nmol/L/hr (indicative age-related range <11 nmol/L/hr). He was started on an amino acid formula to complement breastfeeding for suspected CMPA – skin prick testing confirmed sensitization to milk, nuts and house dust mites, with concerns of delayed soya allergy, so his mother continued to exclude these. At 3 months postdischarge, his eczema had improved considerably and renin levels had normalized.

This study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was not required as it is a retrospective case series describing clinical observations without experimental intervention. Written informed consent was obtained from the parent/legal guardian for publication of these case reports.

Discussion

These cases suggest an association between severe AD and biochemical features of secondary (physiological) hyperaldosteronism—hyponatremia and hyperkalemia, with high renin and/or aldosterone levels and appropriate mineralocorticoid-driven renal reabsorption of sodium. This association is further strengthened by the resolution of biochemical disturbances after topical treatment of AD, avoidance of food allergens, and improved weight gain, supporting an extrarenal mechanism of electrolyte disturbance.

In normal circumstances, aldosterone functions as part of the RAAS to regulate ECV and blood pressure [1]. Aldosterone acts through the mineralocorticoid receptor, triggering expression of tubular apical epithelial sodium channel (ENaC) and basolateral Na/K antiporter, resulting in sodium reabsorption, potassium excretion and subsequent aquaporin-2-mediated water reabsorption, driven by antidiuretic hormone (ADH) secretion [2]. Low urinary sodium concentrations, therefore, reflect effective aldosterone action. In contrast, disorders of aldosterone action such as PHA are characterized by hyponatremia, hyperkalemia and hypovolemia due to renal salt-wasting, despite elevated aldosterone levels. Each of our cases demonstrated PHA-like electrolyte disturbances and RAAS activation, but with low urinary sodium levels in both cases where these were measured, in keeping with secondary, or physiological, hyperaldosteronism. While concurrent elevation of both plasma aldosterone and renin at the time of electrolyte derangement was only seen in case 2, the urinary steroid profiles (USPs) of cases 1 and 3 showed relative increases of corticosterone and aldosterone metabolites and the aldosterone precursor tetrahydroaldosterone, reflecting mineralocorticoid pathway hyperstimulation. Of note, the USPs of PHA and secondary hyperaldosteronism are biochemically largely indistinguishable, except for the difference in urinary electrolyte values demonstrated in our cases. The moderately elevated aldosterone and normal renin levels in case 1 likely reflect the delay in sampling, 3 months after the initial presentation. Interestingly, hyperkaliemia also directly stimulates aldosterone secretion, independently of RAAS activation, via potassium-sensitive channels in the adrenal cortex [1], so it is possible that, given the severity and duration of hyperkalemia in case 1, this contributed to raising aldosterone levels despite normal renin levels. In case 3, sodium supplementation was given before plasma renin/aldosterone measurements, which may explain the comparatively modest rise in aldosterone. Nonetheless, the USP findings in both of these cases provide evidence of RAAS activation concurrently with hyponatremias and hyperkalemia.

Renin release and RAAS activation typically occur in parallel with ADH secretion secondary to intravascular volume depletion, via renal afferent arteriole mechanoreceptors and carotid sinus baroreceptors [1,2]. In AD, volume depletion may occur through transepidermal water loss (TEWL), which measures disruption in skin barrier function [6]. While no current studies directly examine the relationship between TEWL and vascular volume, it has been shown to correlate directly with ADH levels in severe AD, serving as an indirect marker of intravascular volume [2,7]. Nonetheless, determining the osmotic gradient driving water loss through the skin remains challenging. We hypothesize that disruption of the skin barrier in AD leads to both TEWL and increased sodium and protein loss, leading to the hyponatremia and hypoalbuminemia seen in our patients. A growing body of research suggests that skin sodium concentration is increased in AD, playing a key role in osmoregulation and immunity [8], but pediatric studies on this remain sparse. In addition, studies have demonstrated increased transepidermal protein loss in AD [9], with hypoalbuminemia improving after adequate management with topical preparations [10]. This is consistent with our finding of hypoalbuminemia and hypoproteinemia in all 3 patients and with much of the literature on AD [4,9,10].

Intravascular fluid depletion may also follow loss of protein and sodium in the gastrointestinal tract; our patients presented with vomiting, nutritional and growth impairment, and/or hypoalbuminemia linked to food allergies. Evidence suggests that gastrointestinal permeability is increased in AD due to eosinophilic infiltration and inflammation [11], and protein-losing enteropathy has also been reported [12]. Hypoalbuminemia in AD may also reflect reduced protein synthesis from malnutrition, dietary restrictions or interstitial "thirdspacing" of albumin due to increased capillary permeability in chronic inflammation [10]. Indeed, our patients had significant leukocytosis (>40×109/L, predominantly lymphocytes/eosinophils) and thrombocytosis, common in chronic inflammation [13]. While the mechanisms of protein loss remain debated, albumin's role in colloid osmotic pressure suggests hypoalbuminemia in severe AD could activate RAAS through extravascular shifts of water and reduced ECV, irrespective of clinical fluid status [14]. In our patients, the contribution of adequate nutritional management to the resolution of the laboratory findings is difficult to separate from dermatological interventions.

The findings of low urinary sodium in 2 of our cases support an extrarenal mechanism of hyponatremia. Renal sodium reabsorption occurs primarily in proximal tubules in an unregulated manner, relying on osmotic gradients with angiotensin II modulation. In cortical distal nephrons it is precisely controlled by aldosterone and can reduce urinary sodium to less than 0.1% [1,15]. Low urinary sodium levels in our cases demonstrate that aldosterone is appropriately upregulated and effective in AD. We therefore suggest that persistent hyponatremia occurs through profound skin and/or gastrointestinal losses that cannot be fully compensated for by renal reabsorption, possibly exacerbated by excessive water ingestion in chronic inflammatory states [16] and/ or inadequate salt intake due to dietary restrictions or lower sodium levels in breast milk.

Despite these suspected fluid shifts, GFR was normal in all 3 cases, suggesting that the observed hyperkalemia is not due to reduced renal blood flow from volume depletion [4]. In primary PHA, hyperkalemia results from distal tubule resistance to aldosterone, requiring sodium supplementation to excrete potassium. This does not explain persistent hyperkalemia in our cases— the absence of urinary salt-wasting implies effective aldosterone action with sodium reabsorption from renal filtrate. Potassium excretion should therefore follow in exchange, leading to hypokalemia, as in pseudo-Bartter syndrome typical of cystic fibrosis [17]. Interestingly, hyponatremia associated with hyperkalemia also occurs in children with isolated carbonic anhydrase 12 mutations in sweat glands [18] and in excessive gastrointestinal losses from high-output stoma [19]. We postulate that severe and chronic extrarenal sodium losses, combined with proximal renal reabsorption, reduce sodium delivery to distal nephrons and collecting ducts [1,4,15], impairing luminal negative voltage required for potassium excretion via renal outer medullary potassium channel (ROMK). This may be exacerbated by WNK4 activity, which under certain conditions (volume depletion, high angiotensin II) directly inhibits ROMK, Na+-Cl+ cotransporter, and ENaC, leading to reabsorption of potassium and sodium [15]. Indeed, WNK4 missense mutations underlie the hyperkalemia and hypertension seen in Gordon syndrome [20]. In addition, extracellular shifts of potassium due to epidermal cell lysis and metabolic acidosis [1,3] and reduced insulin-dependent intracellular shifts due to low muscle volume and growth restriction [15] may contribute to hyperkalemia. Fig. 1 summarizes the possible mechanisms of secondary hyperaldosteronism and biochemical disturbances in severe AD.

Fig. 1.

Diagram demonstrating the proposed mechanisms that underlie the electrolyte disturbances in severe atopic dermatitis in children. Na+, sodium; K+, potassium; ECV, effective circulating volume; GI, gastrointestinal; TEWL, transepidermal water loss.

The 3 cases described above add to a growing body of research highlighting the profound effects of severe infantile AD on physiological status. The association between AD and electrolyte disturbances is well established, and while transepidermal sodium and water loss appears to drive these changes, rigorous research is needed to elucidate underlying mechanisms. Nevertheless, these cases underline the nature of infantile AD as a multisystem disorder and the importance of a holistic assessment of children with severe AD. Consideration must be given to the possibility of acute deteriorations related to hypovolemia and electrolyte imbalances, as well as long-term effects of hypoalbuminemia and chronic inflammation, both of which emphasize the need for prompt and effective treatment of infantile AD.

Notes

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Acknowledgments

The authors thank the patients and their families. We are grateful to Sophie Barnes, Consultant Clinical Scientist at Charing Cross Hospital, for her invaluable help in analyzing and interpreting the renin/aldosterone levels and providing age-related ranges.

Author contribution

Conceptualization: AMMCJ, ED; Visualization: AMMCJ; Writing - original draft: AMMCJ; Writing - review & editing: DRT, NM, RRK, ED

References

1. Stewart PM, Newell-Price JDC. The adrenal cortex. In : Melmed S, ed. Williams textbook of endocrinology 13th edth ed. Philadelphia: Elsevier; 2016. p. 489–555.
2. Boone M, Deen PM. Physiology and pathophysiology of the Vasopressin-regulated renal water reabsorption. Pflugers Arch 2008;456:1005–24.
3. Bizzarri C, Pedicelli S, Cappa M, Cianfarani S. Water balance and 'salt wasting' in the first year of life: the role of Aldosterone-signaling defects. Horm Res Paediatr 2016;86:143–53.
4. Adachi M, Takamasu T, Inuo C. Hyponatremia secondary to severe atopic dermatitis in early infancy. Pediatr Int 2019;61:544–50.
5. Corry DB, Tuck ML. Secondary aldosteronism. Endocrinol Metab Clin North Am 1995;24:511–29.
6. Al S, Asilsoy S, Atay O, Kangallı O, Atakul G, Tezcan D, et al. Transepidermal water loss in allergic diseases. Allergy Asthma Proc 2023;44:186–92.
7. Aoki T. Serum antidiuretic hormone is elevated in relation to the increase in average total body transepidermal water loss in severe atopic dermatitis. Br J Dermatol 2005;153:359–63.
8. Chattopadhyay A, Tully J, Shan J, Sheikh S, Ohliger M, Gordon JW, et al. Sodium in the skin: a summary of the physiology and a scoping review of disease associations. Clin Exp Dermatol 2023;48:733–43.
9. Nomura I, Katsunuma T, Tomikawa M, Shibata A, Kawahara H, Ohya Y, et al. Hypoproteinemia in severe childhood atopic dermatitis: a serious complication. Pediatr Allergy Immunol 2002;13:287–94.
10. Jo SY, Lee CH, Jung WJ, Kim SW, Hwang YH. Common features of atopic dermatitis with hypoproteinemia. Korean J Pediatr 2018;61:348–54.
11. Leyva-Castillo JM, Galand C, Kam C, Burton O, Gurish M, Musser MA, et al. Mechanical skin injury promotes food anaphylaxis by driving intestinal mast cell expansion. Immunity 2019;50:1262–75.e4.
12. Fujita Y, Nomura K, Yoshihara S. Protein-losing enteropathy in an infant with severe atopic dermatitis. BMJ Case Rep 2021;14e241057.
13. Dame C, Sutor AH. Primary and secondary thrombocytosis in childhood. Br J Haematol 2005;129:165–77.
14. Gounden V, Vashisht R, Jialal I. Hypoalbuminemia In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
15. Meneton P, Loffing J, Warnock DG. Sodium and potassium handling by the Aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol 2004;287:F593–601.
16. Baez G, Chirio M, Pisula P, Seminario E, Carasa N, Philippi R, et al. Hyponatremia and malnutrition: a comprehensive review. Ir J Med Sci 2024;193:1043–6.
17. Vilotijević-Dautović G, Stojanović V. Pseudo-Bartter's syndrome in patients with cystic fibrosis: a case series and review of the literature. Srp Arh Celok Lek 2015;143:748–51.
18. Muhammad E, Leventhal N, Parvari G, Hanukoglu A, Hanukoglu I, Chalifa-Caspi V, et al. Autosomal recessive hyponatremia due to isolated salt wasting in sweat associated with a mutation in the active site of Carbonic Anhydrase 12. Hum Genet 2011;129:397–405.
19. Ou CY, Chen YJ, Lin GB, Chen MF, Chia ST. Case report: newborns with pseudohypoaldosteronism secondary to excessive gastrointestinal losses through high output stoma. Front Pediatr 2021;9:773246.
20. Murillo-de-Ozores AR, Rodríguez-Gama A, Carbajal-Contreras H, Gamba G, Castañeda-Bueno M. WNK4 kinase: from structure to physiology. Am J Physiol Renal Physiol 2021;320:F378–403.

Article information Continued

Fig. 1.

Diagram demonstrating the proposed mechanisms that underlie the electrolyte disturbances in severe atopic dermatitis in children. Na+, sodium; K+, potassium; ECV, effective circulating volume; GI, gastrointestinal; TEWL, transepidermal water loss.

Table 1.

Laboratory results

Variable Reference range Case 1
Case 2
Case 3
9 Mo* 12 Mo 20 Mo 7 Mo* 11 Mo 5 Mo* 8 Mo
Sodium (mmol/L) 136–145 129 139 139 115 137 121 138
Potassium (mmol/L) 3.5–5.1 7.4 5.1 4 6.4 4.1 6.3 4
Aldosterone (pmol/L) <2,000 (<1 yr), <1,000 (1–6 yr) - 6,750 <120 >40,000 140 3,360 <240
Renin (nmol/L/hr) <11 (<1 yr), <8 (1–6 yr) - 3.4 0.9 22.4 1.2 88.3 0.9
Albumin (g/L) 35–52 25 29 - 28 37 27 -
Total protein (g/L) 44–76 48 44 - 39 59 43 -
SeOsm (mmol/kg) 275–295 284 - - 242 - 283 -
Platelets (×109/L) 150–410 448 - 326 784 471 659 371
WCC (×109/L) 6–16 16.4 - 8.3 40.6 12 49.2 12.5
Creatinine (umol/L) 15–37 <15 - 25 25 <15 <15 19
Urea (mmol/L) 1.2–5 2 - 4.6 - - -
Urine results Case 1 (at presentation–9 mo) Case 3 (at presentation–5 mo)
 UNa (mmol/L) No range 8 7
 UOsm (mmol/kg) No range - 270
 USP No range Corticosterone metabolites, aldosterone precursors and major aldosterone metabolite Corticosterone metabolites and major aldosterone metabolite

SeOsm, serum osmolality; WCC, white cell count; UNa, urine sodium; UOsm, urine osmolality; USP, urine steroid profile.

*

At presentation.

Table 2.

Weight trends – from birth, pre-, and posttreatment

Variable Case 1
Case 2
Case 3
Birth 9 Mo 20 Mo Birth 7 Mo 11 Mo Birth 5 Mo 8 Mo
Weight (kg) 2.82 6.52 11.36 3.19 4.34 8.68 2.82 6.28 8.2
Centile 47th <0.4th 59th 21st <0.4th 21st 47th 11th 25th–50th